About Kenvue Inc.
https://www.kenvue.comKenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.
CEO
Thibaut Mongon
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 743
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Jefferies
Buy
B of A Securities
Buy
Rothschild & Co
Buy
JP Morgan
Overweight
Piper Sandler
Overweight
Barclays
Equal Weight
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:233.35M
Value:$3.99B
BLACKROCK, INC.
Shares:144.77M
Value:$2.48B
BLACKROCK INC.
Shares:122.78M
Value:$2.1B
Summary
Showing Top 3 of 1,150
About Kenvue Inc.
https://www.kenvue.comKenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.76B ▼ | $1.6B ▲ | $398M ▼ | 10.57% ▼ | $0.21 ▼ | $760M ▼ |
| Q2-2025 | $3.84B ▲ | $1.57B ▼ | $420M ▲ | 10.94% ▲ | $0.22 ▲ | $837M ▲ |
| Q1-2025 | $3.74B ▲ | $1.61B ▲ | $322M ▲ | 8.61% ▲ | $0.17 ▲ | $701M ▲ |
| Q4-2024 | $3.66B ▼ | $1.59B ▼ | $293M ▼ | 8% ▼ | $0.15 ▼ | $644M ▼ |
| Q3-2024 | $3.9B | $1.63B | $383M | 9.82% | $0.2 | $855M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.14B ▲ | $27.25B ▲ | $16.61B ▲ | $10.63B ▼ |
| Q2-2025 | $1.07B ▲ | $27.13B ▲ | $16.4B ▲ | $10.73B ▲ |
| Q1-2025 | $1.06B ▼ | $26.26B ▲ | $16.2B ▲ | $10.05B ▲ |
| Q4-2024 | $1.07B ▲ | $25.6B ▼ | $15.93B ▼ | $9.67B ▼ |
| Q3-2024 | $1.06B | $26.93B | $16.28B | $10.64B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $398M ▼ | $294M ▼ | $-104M ▼ | $-110M ▲ | $1.14B ▲ | $196M ▼ |
| Q2-2025 | $420M ▲ | $621M ▲ | $-90M ▲ | $-548M ▼ | $-1.06B ▼ | $533M ▲ |
| Q1-2025 | $322M ▲ | $428M ▼ | $-167M ▼ | $-310M ▲ | $-13M ▼ | $249M ▼ |
| Q4-2024 | $293M ▼ | $793M ▲ | $-132M ▼ | $-587M ▼ | $13M ▼ | $661M ▲ |
| Q3-2024 | $383M | $249M | $-56M | $-162M | $43M | $190M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Essential Health | $1.08Bn ▲ | $1.10Bn ▲ | $1.23Bn ▲ | $1.16Bn ▼ |
 Self Care | $1.57Bn ▲ | $1.67Bn ▲ | $1.55Bn ▼ | $1.56Bn ▲ |
 Skin Health and Beauty | $1.01Bn ▲ | $980.00M ▼ | $1.06Bn ▲ | $1.04Bn ▼ |
CEO
Thibaut Mongon
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 743
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Jefferies
Buy
B of A Securities
Buy
Rothschild & Co
Buy
JP Morgan
Overweight
Piper Sandler
Overweight
Barclays
Equal Weight
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:233.35M
Value:$3.99B
BLACKROCK, INC.
Shares:144.77M
Value:$2.48B
BLACKROCK INC.
Shares:122.78M
Value:$2.1B
Summary
Showing Top 3 of 1,150